Last reviewed · How we verify
BNT162b1
mRNA-based vaccine
mRNA-based vaccine Used for COVID-19 prevention.
At a glance
| Generic name | BNT162b1 |
|---|---|
| Sponsor | BioNTech SE |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
BNT162b1 is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the SARS-CoV-2 spike protein.
Approved indications
- COVID-19 prevention
Common side effects
- Pain at injection site
- Fatigue
- Headache
Key clinical trials
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Characterizing Postoperative T and B Cell Dysfunction in Cancer Surgery Patients, Using COVID-19 as a Model Antigen
- A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b1 CI brief — competitive landscape report
- BNT162b1 updates RSS · CI watch RSS
- BioNTech SE portfolio CI